Company profile SLRX
There is not enough data for Salarius Pharmaceuticals Seclidemstat to provide analysis
There is not enough data for Salarius Pharmaceuticals Seclidemstat to provide correlation calculation
There is not enough data for Salarius Pharmaceuticals Seclidemstat to provide analysis
There is not enough data for SP-2577 to provide analysis
There is not enough data for SP-2577 to provide correlation calculation
There is not enough data for SP-2577 to provide analysis
After 39 days of this quarter the interest is at 83.0. Based on that we can calculate that during remaining 52 days it will total up to 194.0. That appears to be equal to previous quarter and same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 159 | 236 48.4% QoQ | 219 -7.2% QoQ | 344 57.1% QoQ |
| 2020 | 193 21.4% YoY -43.9% QoQ | 247 4.7% YoY 28.0% QoQ | 193 -11.9% YoY -21.9% QoQ | 181 -47.4% YoY -6.2% QoQ |
| 2021 | 184 -4.7% YoY 1.7% QoQ | 219 -11.3% YoY 19.0% QoQ | 175 -9.3% YoY -20.1% QoQ | 176 -2.8% YoY 0.6% QoQ |
| 2022 | 205 11.4% YoY 16.5% QoQ | 201 -8.2% YoY -2.0% QoQ | 265 51.4% YoY 31.8% QoQ | 196 11.4% YoY -26.0% QoQ |
| 2023 | 273 33.2% YoY 39.3% QoQ | 202 0.5% YoY -26.0% QoQ | 184 -30.6% YoY -8.9% QoQ | 212 8.2% YoY 15.2% QoQ |
| 2024 | 83 -69.6% YoY -60.8% QoQ | - | - | - |
The average 5 years interest of Ewing sarcoma was 16.66 per week. The last year interest of Ewing sarcoma compared to the last 5 years has changed by -7.44%. This is something to be checked. The last year interest is quite lower compared to 5 years ago. It has decreased by -23.7%.
There is not enough data for SP-3164 to provide analysis
There is not enough data for SP-3164 to provide correlation calculation
There is not enough data for SP-3164 to provide analysis
There is not enough data for small molecular protein degrader to provide analysis
There is not enough data for small molecular protein degrader to provide correlation calculation
There is not enough data for small molecular protein degrader to provide analysis
There is not enough data for hematological tumors to provide analysis
There is not enough data for hematological tumors to provide correlation calculation
There is not enough data for hematological tumors to provide analysis
After 39 days of this quarter the interest is at 267.0. Based on that we can calculate that during remaining 52 days it will total up to 623.0. That appears to be equal to previous quarter and same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 306 | 412 34.6% QoQ | 434 5.3% QoQ | 380 -12.4% QoQ |
| 2020 | 401 31.0% YoY 5.5% QoQ | 417 1.2% YoY 4.0% QoQ | 435 0.2% YoY 4.3% QoQ | 471 23.9% YoY 8.3% QoQ |
| 2021 | 435 8.5% YoY -7.6% QoQ | 384 -7.9% YoY -11.7% QoQ | 402 -7.6% YoY 4.7% QoQ | 440 -6.6% YoY 9.5% QoQ |
| 2022 | 643 47.8% YoY 46.1% QoQ | 619 61.2% YoY -3.7% QoQ | 517 28.6% YoY -16.5% QoQ | 494 12.3% YoY -4.4% QoQ |
| 2023 | 724 12.6% YoY 46.6% QoQ | 643 3.9% YoY -11.2% QoQ | 597 15.5% YoY -7.2% QoQ | 585 18.4% YoY -2.0% QoQ |
| 2024 | 267 -63.1% YoY -54.4% QoQ | - | - | - |
The average 5 years interest of solid tumors was 38.34 per week. The last year interest of solid tumors compared to the last 5 years has changed by 25.04%. The interest for solid tumors is trending. The last year interest is quite higher compared to 5 years ago. It has increased by 46.02%.
There is not enough data for Salarius Pharmaceuticals compensation to provide analysis
There is not enough data for Salarius Pharmaceuticals compensation to provide correlation calculation
There is not enough data for Salarius Pharmaceuticals compensation to provide analysis
Google Trends for Salarius Pharmaceuticals clinical trial
Not enough data for reliable calculations!
There is not enough data for Salarius Pharmaceuticals clinical trial to provide analysis
There is not enough data for Salarius Pharmaceuticals clinical trial to provide correlation calculation
There is not enough data for Salarius Pharmaceuticals clinical trial to provide analysis